Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine

Name: Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine
License: Public Domain

Assistance Publique - Hôpitaux de Paris

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

covid

vaccine reaction, covid-19

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 467623
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.